rongsheng north america inc free sample

Rongsheng Machinery Manufacture Ltd of Huabei Oilfield, Hebei, which was founded in 1976, has now been an internationally famous comprehensive petroleum machinery manufacturer, and has grown to be the largest manufacturer and dealer of land-use BOPs.

The company products include BOPs, BOP control system, choke and kill manifolds, snubbing equipment, mud pump, wellhead equipment and Christmas tree, pumping units, tubing and drill pipe joint, etc, which have all passed certification by American Petroleum Institute (API). Four categories out of these products, namely BOPs, BOP control system, choke and kill manifolds and mud pumps, have passed certification of GOST and RTN in Russia.

NOTE: Rongsheng North America, Inc. is the only legal subsidiary of Rongsheng Machinery Manufacture Ltd. in the United States which is authorized to sell "HRSB" brand products including BOP"s, Mud Pumps and Well Heads.

Key Companies Covered in the Antibody Drugs Research are Shanghai Rongsheng, Merck & Co., Glaxosmithkline, Adaltis S.r.l., Seattle Genetics Inc., Dominion Biologicals Limited, Beijing Baitai Pharma, DiaSorin S.p.A. UK Branch, Johnson & Johnson, UCB Company, Alexion Pharmaceuticals, Abbott Laboratories, Spectrum Pharmaceuticals, Hoffman-La Roche, Takeda Pharmaceutical U.S.A. Inc., Bristol-Myers Squibb, Amgen, Ortho-Clinical Diagnostics., Eli Lilly And Co., Novartis, Wuhan Institute of Biological Products, Biogen Idec and other key market players.

Chapter 1 is the basis of the entire report. In this chapter, we define the market concept and market scope of Antibody Drugs, including product classification, application areas, and the entire report covered area.

Chapter 3 focuses on analyzing the current competitive situation in the Antibody Drugs market and provides basic information, market data, product introductions, etc. of leading companies in the industry. At the same time, Chapter 3 includes the highlighted analysis–Strategies for Company to Deal with the Impact of COVID-19.

Chapter 6 includes detailed data of major regions of the world, including detailed data of major regions of the world. North America, Asia Pacific, Europe, South America, Middle East and Africa.

Provide market entry strategy analysis for new players or players who are ready to enter the market, including market segment definition, client analysis, distribution model, product messaging and positioning, and price strategy analysis.

Key Market Features in Global Market:The report assessed key market features, including revenue, capacity, price, capacity utilization rate, production rate, gross, production, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. The study also offers a thorough analysis of the most important market factors and their most recent developments, as well as pertinent market segments and sub-segments.

Amgen Launches Amjevita, a biosimilar to AbbVie"s Humira adalimumab, in US to treat seven inflammatory diseases including moderate-to-severe rheumatoid arthritis in adults; Amjevita’s wholesale acquisition cost is 55% below current Humira list price

This research report primarily based on Blowout Preventers market and covers Market Study Report includes current and upcoming industry trends further to the global spectrum of the Blowout Preventers market that includes distinct regions. Likewise, the report additionally expands on elaborate information concerning contributions by way of key vendors, demand, and deliver evaluation as well as market proportion boom of the Blowout Preventers industry.

Some of the key players inside the Blowout Preventers market are Cameron International Corporation, Control Flow Inc, General Electric Oil and Gas, Greenes Energy Group, LLC, National Oilwell Varco, Proserv Group Inc, Rigmanufacturer, Rongsheng Machinery Manufacture Ltd., UZTEL S.A..

By geography, the Blowout Preventers market can be segmented into North America, Latin America, Western Europe, Eastern Europe, China, Japan, SEA others in Asia Pacific and Middle East Africa. Among these regions, the North America Blowout Preventers market is anticipated to dominate the worldwide Blowout Preventers market throughout the forecast length. The Asia Pacific (such as Japan and China) Blowout Preventers market and the Europe Blowout Preventers market are predicted to follow the North America Blowout Preventers market within the global Blowout Preventers market in phrases of revenue. The China Blowout Preventers market is predicted to showcase the highest boom charge throughout the forecast length. The Latin America Blowout Preventers market is additionally anticipated to witness a vast growth price throughout the forecast period.

The studies report serves a thorough assessment of the Blowout Preventers market and carries thoughtful insights, facts, historical data, and statistically supported and industry-validated market statistics. Furthermore, it carries projections using a suitable set of assumptions and methodologies. The studies report provides analysis and information consistent with Blowout Preventers market segments which include type, location, and region.

Extensive info pertaining to the market share garnered with the aid of each software, as well as the details of the anticipated increase rate and product intake to be accounted for by way of every application have been provided.

The relevant fee and sales inside the Blowout Preventers market together with the foreseeable growth traits for the Blowout Preventers market is included inside the report.

Jeffrey J. Stanton: ude.mcb@jnotnats; Sally Nofs: ude.mcb@sfon; Rongsheng Peng: ude.mcb@gnepr; Gary S. Hayward: ude.imhj@drawyahg; Paul D. Ling: ude.mcb@gnilp

Elephantid herpesviruses, commonly known as Elephant endotheliotropic herpesviruses (EEHVs), are most closely related to the Betaherpesvirinae sub-family and are assigned to the Proboscivirus genus (Davison et al., 2009; Richman and Hayward, 2011). EEHVs are associated with lethal hemorrhagic disease in Asian (Elephas maximus) and African (Loxodonta africana) elephants with more than 70 cases of EEHV-associated elephant deaths being reported worldwide (Ehlers et al., 2001; Fickel et al., 2001; Garner et al., 2009; Ossent et al., 1990; Richman and Hayward, 2011; Richman et al., 1999; Richman, Montali, and Hayward, 2000; Zachariah, 2008). EEHV-associated hemorrhagic disease is most common in juvenile captive-born Asian elephants and deaths due to EEHV infection account for approximately 60% of the overall mortality rate of captive-born Asian elephants in North America (Richman and Hayward, 2011). Although the investigation and understanding of the impact of the EEHVs is in it’s infancy, preliminary evidence suggest that overall, they represent a significant source of morbidity and mortality in elephants worldwide.

There are currently seven distinct EEHV types that have been identified based on viral DNA sequence analysis. EEHV2, EEHV3, EEHV4, EEHV5, and EEHV6 differ from EEHV1 by between 15 to 35% at the nucleotide level in several well conserved genes and from each other by 8 to 35% (Latimer et al., 2011; Richman and Hayward, 2011). Therefore, they all rate as distinct species, whereas EEHV1A and EEHV1B are complex partially related chimeric sub-species. EEHV1A and 1B have been responsible for the vast majority of EEHV-associated deaths in elephants (Garner et al., 2009; Latimer et al., 2011; Richman et al., 1999; Zong et al., 2007). EEHV2 has been associated with the deaths of two African elephants while EEHV3 and 4 have been associated with the death of one Asian elephant calf each (Garner et al., 2009; Latimer et al., 2011; Richman et al., 1999). EEHV5 was originally detected in blood samples from an apparently healthy wild-born adult Asian elephant and EEHV4 was detected in blood samples from a clinically ill African elephant calf that survived the infection (Latimer et al., 2011). Although the existence of at least these 7 types of Probosciviruses is known, the prevalence of EEHV infection and distribution of EEHV species amongst in situ or ex situ elephant populations remains to be determined.

Previously, a quantitative real-time polymerase chain reaction (qPCR) assay was developed that detects both forms of the EEHV1 species (1A and 1B) and used this assay to screen multiple fluid samples from healthy and clinically ill Asian elephants (Stanton et al., 2010). We demonstrated that EEHV1 is detected commonly in trunk secretions from apparently healthy captive Asian elephants and used viral genotypic analysis on EEHV1 viral DNA to establish the first epidemiologic connection between healthy Asian elephants shedding a virus that had previously been associated with the death of a calf in the same herd. In addition, it was found that knowledge of EEHV viral loads in blood samples and trunk washes is useful for the management of animals infected with EEHV (Stanton et al., 2012). The purpose of the current study was to develop and validate four more similar specific and sensitive qPCR assays that independently detect EEHV2, 3/4, 5, and 6. This work will provide novel assays to include in diagnostic testing for clinically ill elephants and for future studies regarding the overall prevalence of EEHV infection amongst in situ and ex situ Asian elephants.

All samples were collected from Asian elephants as part of their routine medical care or during necropsy. Preparation of DNA samples from North American Proboscivirus (NAP) cases 19, and 31 and 34 (EEHV1A) plus 22 (EEHV4), 27 (EEHV3) and negative control Asian elephants have been previously described (Stanton et al., 2010). DNA was prepared from NAP12 (EEHV2) and NAP35 (EEHV6) (Latimer et al., 2011; Richman et al., 1999) using a Gentra Capture Column Kit (Gentra Systems, Minneapolis, MN) and the manufacturers recommended protocol. DNA was prepared from NAP45 (EEHV1B, Genbank accession {"type":"entrez-nucleotide","attrs":{"text":"JN633891.1","term_id":"373940278","term_text":"JN633891.1"}}JN633891.1) and NAP50 (EEHV5, Genbank accession {"type":"entrez-nucleotide","attrs":{"text":"JN983108.1","term_id":"364505808","term_text":"JN983108.1"}}JN983108.1) using a Qiagen DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) and the manufacturers recommended protocol. Genomic elephant DNA used for diluting standards was prepared as described previously (Stanton et al., 2010).

All EEHV qPCR assays were performed using reagents and thermocycling conditions as previously described for the EEHV1 assay (Stanton et al., 2010). DNA primers and 5′-hydrolysis probes were selected using Primer Express software version 3.0 (Applied Biosystems/Life Technologies Inc., Carlsbad, CA). Oligonucleotide primers were ordered from Integrated DNA Technologies, Inc. (Coralville, IA). Hydrolysis probes were ordered from Applied Biosystems/Life Technologies Inc. (Carlsbad, CA). Assays were performed using a StepOne thermocycler and StepOne software package version 2.1 (Applied Biosystems/Life Technologies Inc., Carlsbad, CA) as previously described (Stanton et al., 2010). No template control (NTC) reactions in which water was added instead of test DNA were included with every qPCR assay. Assays were only considered valid and included in this study if NTC reactions produce Cq greater than or equal to 40.

Using available DNA sequence data for EEHV3 ({"type":"entrez-nucleotide","attrs":{"text":"EU658937.1","term_id":"194399834","term_text":"EU658937.1"}}EU658937.1) and EEHV5 ({"type":"entrez-nucleotide","attrs":{"text":"JN983114.1","term_id":"364505825","term_text":"JN983114.1"}}JN983114.1), target DNA sequences for these two viruses were amplified by standard PCR, as described previously (Stanton et al., 2010). A 299bp product for the EEHV3 terminase gene was amplified using forward primer 5′-TACGTCATTCCTCGCCCATGTGAA-3′ and reverse primer 5′-TGCTGTAGCGGATCATGTCGAACT-3′. A 500bp product for the EEHV5 POL gene was amplified using forward primer 5′-CCTATGTTATTGTACCTTAGTT-3′ and reverse primer 5′-CAGAACTTTCCACTATCGACA-3′. Both PCR products were cloned into the commercially available pCR Blunt cloning vector (Invitrogen/Life Technologies Inc., Carlsbad, CA) to generate plasmids pRSP724 (EEHV3 terminase) and pRSP796B (EEHV5 DNA polymerase). The recombinant plasmids pRSP724 and pRSP796B were linearized using BamHI or HindIII respectively, purified using a commercially available kit (QIAGEN Inc., Hilden, Germany), and quantified using a commercially available DNA fluorometer kit (Qubit, Invitrogen/Life Technologies Inc., Carlsbad, CA). Oligonucleotides corresponding to the positive DNA strand of the target sequences were ordered from Integrated DNA Technologies, Inc. (Coralville, IA) for construction of the EEHV2 and EEHV6 calibration curves. Lyophilized oligonucleotides were diluted to a concentration of 100 μM (6.02 × 1013 copies/μL) in distilled and deionized sterile water. For plasmids, the following formula was used to calculate copies target sequence per μL: [(6.02 × 1023 copies) × (plasmid concentration in g/μL)]/[(No. of bases) × (660 g/base)]. Linearized plasmids or oligonucleotides were then diluted to known copy number/μL into a solution of 20 ng/μL Asian elephant DNA in AE elution buffer (QIAGEN Inc., Hilden, Germany). The range over which target sequences were tested was 10 – 1 × 105 copies/test reaction.

In order to determine the individual assay performance characteristics, a calibration curve containing known quantities of target DNA sequence over a range of 1 – 1 × 105 copies per test reaction was diluted into a solution containing 20 ng/μL of Asian elephant DNA known to be negative for the presence of detectable Elephantid herpesvirus DNA. This allowed the determination of the performance of each assay in a complex solution of DNA that simulates clinical samples as closely as possible. At least 5 independent calibration curves were carried out over a range of 10 – 1 × 105 copies target sequence per test reaction for each assay and representative curves are shown in Fig. 1. Using data generated from the calibration curves we determined the PCR efficiency, linear dynamic range, limit of detection (LOD), and the intra assay and inter assay variation for each EEHV qPCR assay (Tables 1–3 and Figure 1). Intra- and inter-assay variability for the published EEHV1 assay is included for comparison (Tables 2 and ​and3).3). Each assay had a robust PCR efficiency (90–110%), a dynamic linear range over 5 log10 concentrations (10 – 1 × 105), a limit of detection of 10 copies/test reaction with 100% sensitivity, and low intra-assay and inter-assay variation.

To validate the specificity of the four newly generated qPCR assays, we utilized archival Asian elephant DNA samples had previously been characterized for the presence of DNA for all known EEHV species (Table 4). A total of 10 archival DNA samples were examined, including samples that had been used previously to validate our EEHV1 qPCR assay (Stanton et al., 2010). We considered a positive assay to be one in which the Cq was less than 40 and those samples with Cq equal to or greater than 40 were considered negative. Any assay in which a NTC reaction produced a positive Cq was considered invalid and not included in the data set. Each assay which was developed proved to be specific for the designed EEHV. The only assay that did exhibit cross-reactivity between different EEHV species was the EEHV3/4 assay and this was an expected result based on the high DNA sequence similarity between the EEHV3 and EEHV4 amplicon sequences and the primer design used.

bNorth American Proboscivirus (NAP) number assigned to the test sample. If no NAP number was previously assigned to the case, the elephant’s name is given.

One hypothesis for the devastating lethal effects of EEHV1 in juvenile Asian elephants is because it is the result of a cross-species transmission between an endogenous African elephant virus to Asian elephants (Richman et al., 1999). To answer this question, more studies are needed to assess the prevalence of the different EEHV types within captive and range country Asian and African elephant populations. Previous studies from our group have shown that the EEHV1 qPCR assay detects reliably virus DNA in a wide variety of selected samples, including necropsy tissue and blood from symptomatic animals as well as trunk washes or blood from asymptomatic animals undergoing primary or reactivated infections and shedding (Stanton et al., 2010). The generation of the assays described in this study will provide the requisite tools needed to embark on studies to determine which EEHVs are endogenous to African and Asian elephants.

A difficult management issue for EEHV disease is the short time-frame between appearance of clinical signs and death. However, several Asian elephants have survived severe EEHV-associated disease (Schmitt et al., 2000; Stanton et al., 2012). The survival of these animals was assisted in part by aggressive supportive therapies and administration of anti-herpesviral medications. These novel qPCR assays will facilitate rapid and early diagnosis of potential disease, which would prompt initiation of treatment procedures known to have been associated with the increased rate of survival of other EEHV infected elephants. In addition, these qPCR assays could be used for regular monitoring of susceptible animals where one might even detect emerging viremia prior to the appearance of clinical signs.

This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.

Colloids (blood plasma) can be defined as the liquid component of whole blood, comprising up to 60% of total blood volume, which contains proteins such as serum fibrinogen, albumins, and globulins. Other factors present in blood plasma include clotting factors, glucose, hormones, mineral ions, and carbon dioxide, which enable the use of blood plasma in the treatment of excessive bleeding and other blood related diseases such as gastrointestinal bleeding and hepatitis B virus infection.

Increasing prevalence of chronic and severe diseases around the globe is expected to drive the market in the next few years. According to the Centers for Disease Control & Prevention (CDC), 6 in every 10 adults in America are suffering through chronic diseases and 4 in every 10 adults have 2 or more chronic diseases. Further stated, heart diseases, cancers, chronic lung diseases, and chronic kidney diseases, are some of the chronic diseases which are the leading causes of death in North America. Moreover, rising number of severe diseases in low to middle income countries across the globe is expected to support the market growth.

Increasing prevalence of chronic gastrointestinal bleeding disorders, rising incidences of liver diseases and disorders, and growing number of accidents across the globe resulting in extensive blood loss are some of the factors notably increasing the demand for colloids (blood plasma). According to the National Institute of Diabetes & Digestive and Kidney Diseases, more than 100,000 people suffer from gastrointestinal tract bleeding disorders in the U.S. Colloids (blood plasma) treatment recovers blood and blood plasma volume in the body after heavy blood loss, and thus, the demand for natural and synthetic blood plasma has been increasing. China imported more than 60% of its total blood plasma consumption from the U.S. in 2016 and the demand has been increasing by 15% annually since then. High prevalence of hepatitis B virus in Asian countries is expected to upsurge the demand for blood plasma for effective treatments.

Based on type, the market is segmented into natural type colloids and synthetic type colloids. Natural type colloids consist of water and proteins such as fibrinogen, globulins, and serum albumins. Natural plasma is preferred for the treatment of people suffering from shock, burns, trauma, liver diseases, and hepatitis B virus infection. Rising awareness regarding the benefits of blood donation in increasing production of colloids (blood plasma) and increasing prevalence of hepatitis B virus infection in developing regions including Asia Pacific and Africa, are some of the key factors driving the growth of the natural type colloid segment. Synthetic type colloids are derived from fluorine and carbon containing chemicals that are chemically inert in nature and highly effective in dissolving, absorbing, and transporting oxygen in lungs and throughout the body. The robust nature of synthetic blood plasma and its quality of surviving harsh environments such as no-refrigeration and pre-hospital are expected to drive the growth of the synthetic type colloids segment.

North America dominates the global colloids (blood plasma) market. Increasing incidences of people suffering from burns, especially over the past few years, have been contributing to the growth of the colloids market in North America. According to the National Burn Repository (NBR) of the American Burn Association (ABA), in 2016, more than 486,000 burn injuries were recorded in the U.S., which received medical treatment for severe burns. High effectiveness of blood plasma treatment in severe burn injuries and growing awareness regarding the treatment are projected to bolster market growth in the future. The prevalence of liver disorders among Chinese patients is providing impetus to the import of human serum albumin from the U.S., with a consumption of 300 tons of human serum albumin in 2016. In 2016, 60% of the total consumed human serum albumin in China was imported from the U.S., which has positively influenced the North America colloids market.

Europe accounts for optimum share of the global market. The steady rise in the number of injuries resulting in blood loss is driving the Europe colloids (blood plasma) market. According to the Annual Accident Report of the European Road Safety Observatory, the number of injuries due to accidents resulting in heavy blood loss increased in Europe from around 1.39 million in 2013 to 1.48 million in 2016. Rapid recovery of blood plasma volume due to colloid treatment and increasing number of colloid manufacturers in the region are further aiding market growth.

Some of the major players of the global colloids (blood plasma) market are, CSL Behring, Baxter, Grifols, S.A., Octapharma, Shanghai RAAS Blood Products Co., Ltd., Shandong Taibang Biological Products Co. Ltd (China Biologic Products, Inc.), Hualan Biological Engineering Inc., Chengdu Rongsheng Pharmaceuticals Co., Ltd. (China National Pharmaceutical Group Corporation), and Adma Biologics Inc.

CSL Behring, Baxter, Grifols, S.A., Octapharma, Shanghai RAAS Blood Products Co., Ltd., Shandong Taibang Biological Products Co. Ltd (China Biologic Products, Inc.), Hualan Biological Engineering Inc., Chengdu Rongsheng Pharmaceuticals Co., Ltd. (China National Pharmaceutical Group Corporation), and Adma Biologics Inc.

Rising awareness regarding the benefits of blood donation and increasing prevalence of hepatitis B virus infection are the key factor expected to drive the Colloids (Blood Plasma) Market during forecast period.

Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times, and included in every purchase.